Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.

@article{Brentjens2011SafetyAP,
  title={Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.},
  author={Renier J. Brentjens and Isabelle Rivi{\`e}re and Jae Hoo Park and Marco L Davila and Xiuyan Wang and Jolanta Stefanski and Clare Taylor and Raymond Yeh and Shirley M. Bartido and Oriana B{\'o}rquez-Ojeda and Malgorzata Olszewska and Yvette Bernal and Hollie J. Pegram and Mark Przybylowski and Daniel Hollyman and Yelena Usachenko and Domenick Pirraglia and James Hosey and Elmer Santos and Elizabeth Halton and Peter G. Maslak and David A. Scheinberg and Joseph C Jurcic and Mark Heaney and Glenn Heller and Mark G. Frattini and Michel Sadelain},
  journal={Blood},
  year={2011},
  volume={118 18},
  pages={
          4817-28
        }
}
We report the findings from the first 10 patients with chemotherapy-refractory chronic lymphocytic leukemia (CLL) or relapsed B-cell acute lymphoblastic leukemia (ALL) we have enrolled for treatment with autologous T cells modified to express 19-28z, a second-generation chimeric antigen (Ag) receptor specific to the B-cell lineage Ag CD19. Eight of the 9 treated patients tolerated 19-28z(+) T-cell infusions well. Three of 4 evaluable patients with bulky CLL who received prior conditioning with… CONTINUE READING
Highly Cited
This paper has 375 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 205 extracted citations

CAR-T therapy for leukemia: progress and challenges.

Translational research : the journal of laboratory and clinical medicine • 2017
View 4 Excerpts
Highly Influenced

Chimeric antigen receptor therapy for chronic lymphocytic leukemia: what are the challenges?

Hematology/oncology clinics of North America • 2013
View 6 Excerpts
Highly Influenced

Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy.

Molecular therapy : the journal of the American Society of Gene Therapy • 2018
View 6 Excerpts
Method Support
Highly Influenced

Gene therapy comes of age

Science • 2018
View 8 Excerpts
Highly Influenced

375 Citations

0204060'12'14'16'18
Citations per Year
Semantic Scholar estimates that this publication has 375 citations based on the available data.

See our FAQ for additional information.